Slingshot members are tracking this event:

Celgene (CELG) and Agios pharmaceuticals (AGIO) collaborative product IDHIFA (enasidenib), treatment for acute myeloid leukemia (AML) with IDH2 mutation, granted FDA priority review, with PDUFA decision due August 30

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
CELG Community voting in process
AGIO Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Acute Myeloid Leukemia, Idh2 Mutation, Idhifa, Enasidenib, Pdufa Date